|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
1499095 |
| 003 |
ICU |
| 005 |
19970810133800.0 |
| 008 |
930920s1993 nyua b 001 0 eng c |
| 010 |
|
|
|a 93018737
|
| 020 |
|
|
|a 0824790553 (alk. paper)
|
| 035 |
|
|
|a (ICU)BID17459146
|
| 035 |
|
|
|a (OCoLC)27810490
|
| 040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC$dOrLoB
|
| 050 |
0 |
0 |
|a RL765
|b .C87 1993
|
| 060 |
|
|
|a W1 CL69L v.7 1993
|a WR 300 C9875 1993
|
| 082 |
|
|
|a 616.5/7061
|2 20
|
| 245 |
0 |
0 |
|a Cutaneous antifungal agents :
|b selected compounds in clinical practice and development /
|c edited by John W. Rippon, Robert A. Fromtling.
|
| 260 |
|
|
|a New York :
|b M. Dekker,
|c c1993.
|
| 300 |
|
|
|a xvi, 461 p. :
|b ill. ;
|c 24 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 440 |
|
0 |
|a Clinical dermatology
|v 7
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|t Series Introduction /
|r Alan R. Shalita --
|t Introduction: Antifungal Therapy for Cutaneous Mycoses /
|r John W. Rippon and Robert A. Fromtling --
|g Pt. I.
|t Morpholines.
|g 1.
|t Discovery and Chemistry of Amorolfine /
|r Hans Peter Isenring.
|g 2.
|t Preclinical Data of Amorolfine /
|r Annemarie Polak and Peter George Hartman.
|g 3.
|t The Action of Amorolfine: From Molecule to Cell /
|r Peter George Hartman and Annemarie Polak.
|g 4.
|t Safety of Amorolfine in Healthy Volunteers and Patients /
|r Michael Zaug and Gaetano Roncari.
|g 5.
|t Clinical Efficacy of Amorolfine /
|r Michael Zaug.
|g 6.
|t Clinical Experiences with Amorolfine /
|r Amalia del Palacio --
|g Pt. II.
|t Allylamines.
|t Naftifine.
|g 7.
|t In Vitro and In Vivo Activities of Naftifine /
|r Hubert Mieth.
|g 8.
|t Biochemical Mode of Action of Naftifine /
|r Neil S. Ryder.
|g 9.
|t Clinical Experience with Naftifine /
|r Matthias Brautigam and Gottfried Weidinger.
|t Terbinafine.
|g 10.
|t The Discovery and Chemistry of Terbinafine /
|r Anton Stutz.
|g 11.
|t Biochemical Mode of Action of Terbinafine /
|r Neil S. Ryder.
|g 12.
|t In Vitro and In Vivo Activities of Terbinafine /
|r Hubert Mieth.
|g 13.
|t Clinical Use of Oral and Topical Terbinafine in the Treatment of Fungal Diseases /
|r V. V. Villars and T. C. Jones --
|g Pt. III.
|t Fluconazole.
|g 14.
|t The Discovery of Fluconazole /
|r K. Richardson.
|g 15.
|t Chemistry and Mode of Action of Fluconazole /
|r C. A. Hitchcock and P. J. Whittle.
|g 16.
|t In Vitro and Experimental In Vivo Activities of Fluconazole Against Some Fungi Causing Cutaneous Mycoses /
|r Peter F. Troke.
|g 17.
|t Safety of Fluconazole /
|r Ian H. Osterloh and Nigel D. Pluck.
|g 18.
|t Clinical Efficacy of Fluconazole in the Treatment of Cutaneous Mycoses /
|r Keith W. Brammer --
|g Pt. IV.
|t Itraconazole.
|g 19.
|t Itraconazole: Preclinical Data In Vitro and In Vivo in Cutaneous and Other Superficial Mycoses /
|r Frank C. Odds and Jan Van Cutsem.
|g 20.
|t Discovery, Chemistry, Mode of Action, and Selectivity of Itraconazole /
|r H. Vanden Bossche, Jan Heeres, Leo J. J. Backx, Patrick Marichal and Gustaaf Willemsens.
|g 21.
|t Safety of Itraconazole in Animals and Humans /
|r Ann Lampo, Karel De Beule, Geert Cauwenbergh and Herman Van Cauteren.
|g 22.
|t Clinical Efficacy of Itraconazole: Focus on Cutaneous Infections /
|r Geert Cauwenbergh.
|g 23.
|t Clinical Experience with Itraconazole /
|r E. L. Svejgaard --
|g Pt. V.
|t Compounds in Development.
|t The Nikkomycins.
|g 24.
|t An Overview of Nikkomycins: History, Biochemistry, and Applications /
|r Hans Peter Fiedler, Traugott Schuz and Heinrich Decker.
|g 25.
|t The Use of Nikkomycin Z Singly and in Combination with Azoles for Infections Caused by Candida /
|r Richard F. Hector.
|g 26.
|t Interactions Between Chitin and [beta]-Glucan Synthesis Inhibitors: A New Approach to Antifungal Development for Cutaneous Infections /
|r John R. Perfect.
|t The Pneumocandins.
|g 27.
|t Discovery, Production Process Development, and Isolation of Pneumocandin B[subscript 0] /
|r Robert E. Schwartz, Prakash S. Masurekar and Ray F. White.
|g 28.
|t Chemical and Structure-Activity Studies of the Echinocandin Lipopeptides /
|r Milton L. Hammond.
|g 29.
|t Biological Activity of the Pneumocandins /
|r Ken Bartizal, George K. Abruzzo and Dennis M. Schmatz.
|
| 650 |
|
0 |
|a Dermatomycoses
|x Chemotherapy.
|
| 650 |
|
0 |
|a Antifungal agents
|0 http://id.loc.gov/authorities/subjects/sh85005673
|
| 650 |
|
2 |
|a Antifungal Agents
|x therapeutic use
|
| 650 |
|
2 |
|a Antifungal Agents
|x pharmacokinetics
|
| 650 |
|
2 |
|a Dermatomycoses
|x drug therapy
|
| 650 |
|
7 |
|a Antifungal agents.
|2 fast
|0 http://id.worldcat.org/fast/fst00810512
|
| 650 |
|
7 |
|a Dermatomycoses
|x Chemotherapy.
|2 fast
|0 http://id.worldcat.org/fast/fst00891072
|
| 700 |
1 |
0 |
|a Rippon, John Willard
|0 http://id.loc.gov/authorities/names/n81070776
|1 http://viaf.org/viaf/62867965
|
| 700 |
1 |
0 |
|a Fromtling, Robert A.,
|d 1953-
|0 http://id.loc.gov/authorities/names/n93800839
|1 http://viaf.org/viaf/78001050
|
| 850 |
|
|
|a ICU
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i ad82fc4e-f4b9-5177-b7e3-e3174b3d5ee2
|s fb4ebeac-b77f-5ad7-9787-35ab20ae1301
|
| 928 |
|
|
|t Library of Congress classification
|a RL765.C870 1993
|l ASR
|c ASR-SciASR
|i 2869009
|
| 927 |
|
|
|t Library of Congress classification
|a RL765.C870 1993
|l ASR
|c ASR-SciASR
|e CRERAR
|b 37578593
|i 2891123
|
